Abstract: An apparatus for wireless communications includes a power amplifier, a low-noise amplifier, a power detector, and a transformer. The transformer includes a first inductor coupled to an output of the power amplifier, and a second inductor coupled to an antenna, wherein the second inductor is magnetically coupled with the first inductor. The transformer also includes a third inductor coupled to an input of the low-noise amplifier, wherein the third inductor is magnetically coupled with the second inductor. The transformer also includes a coupling inductor coupled to an input of the power detector, wherein the coupling inductor is magnetically coupled with at least one of the first inductor and the second inductor.

Abstract: A dual mode notch filter for use in a multi-band millimeter wave (mmW) transmitter includes a transmit filter circuit disposed between two amplifiers in a mmW transmit signal path, the transmit filter circuit formed by at least one switch, at least one capacitor, and a double-tuned transformer, the transmit filter circuit having at least two modes configured to selectively filter a spurious signal in at least a first communication band.

Abstract: A dual mode notch filter for use in a multi-band millimeter wave (mmW) transmitter includes a transmit filter circuit disposed between two amplifiers in a mmW transmit signal path, the transmit filter circuit formed by at least one switch, at least one capacitor, and a double-tuned transformer, the transmit filter circuit having at least two modes configured to selectively filter a spurious signal in at least a first communication band.

Abstract: Provided is a T cell receptor (TCR) having a feature of binding to a VLDGLDVLL-HLA A2 complex. The binding affinity of the TCR to the VLDGLDVLL-HLA-A0201 complex is at least 2 times of the binding affinity of a wild-type TCR to the VLDGLDVLL-HLA-A0201 complex. Also provided is a fusion molecule of the TCR and a therapeutic agent. The TCR can be used alone or in combination with a therapeutic agent to target a tumor cell presenting the VLDGLDVLL-HLA-A0201 complex.